Current and historical daily PE Ratio for Galapagos NV (
FRA:GXE
) from 2005 to Apr 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Galapagos NV stock (FRA:GXE) PE ratio as of Apr 24 2024 is 8.59.
More Details
Galapagos NV (FRA:GXE) PE Ratio (TTM) Chart
Galapagos NV (FRA:GXE) PE Ratio (TTM) Historical Data
View and export this data going back to 2005. Start your Free Trial
Total 1224
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Galapagos NV PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-24 | 8.5 | 2024-02-19 | 11.4 |
| 2024-04-23 | 8.5 | 2024-02-16 | 11.4 |
| 2024-04-22 | 8.4 | 2024-02-15 | 11.3 |
| 2024-04-19 | 8.4 | 2024-02-14 | 11.2 |
| 2024-04-18 | 8.4 | 2024-02-13 | 11.3 |
| 2024-04-17 | 8.5 | 2024-02-12 | 11.3 |
| 2024-04-16 | 8.6 | 2024-02-09 | 11.4 |
| 2024-04-15 | 8.8 | 2024-02-08 | 11.1 |
| 2024-04-12 | 9.0 | 2024-02-07 | 11.0 |
| 2024-04-11 | 8.9 | 2024-02-06 | 11.0 |
| 2024-04-10 | 9.0 | 2024-02-05 | 10.7 |
| 2024-04-09 | 9.0 | 2024-02-02 | 10.7 |
| 2024-04-08 | 9.1 | 2024-02-01 | 10.7 |
| 2024-04-05 | 9.1 | 2024-01-31 | 10.8 |
| 2024-04-04 | 9.1 | 2024-01-30 | 10.8 |
| 2024-04-03 | 9.1 | 2024-01-29 | 10.9 |
| 2024-04-02 | 9.2 | 2024-01-26 | 10.8 |
| 2024-03-28 | 9.3 | 2024-01-25 | 10.7 |
| 2024-03-27 | 9.3 | 2024-01-24 | 10.8 |
| 2024-03-26 | 9.3 | 2024-01-23 | 10.8 |
| 2024-03-25 | 9.3 | 2024-01-22 | 10.7 |
| 2024-03-22 | 9.4 | 2024-01-19 | 10.6 |
| 2024-03-21 | 9.5 | 2024-01-18 | 10.7 |
| 2024-03-20 | 9.6 | 2024-01-17 | 10.9 |
| 2024-03-19 | 9.4 | 2024-01-16 | 11.0 |
| 2024-03-18 | 9.7 | 2024-01-12 | 11.2 |
| 2024-03-15 | 9.7 | 2024-01-11 | 11.3 |
| 2024-03-14 | 9.7 | 2024-01-10 | 11.3 |
| 2024-03-13 | 9.8 | 2024-01-09 | 11.8 |
| 2024-03-12 | 9.8 | 2024-01-08 | 11.7 |
| 2024-03-11 | 9.8 | 2024-01-05 | 11.7 |
| 2024-03-08 | 9.7 | 2024-01-04 | 12.0 |
| 2024-03-07 | 9.8 | 2024-01-03 | 11.6 |
| 2024-03-06 | 9.8 | 2024-01-02 | 11.7 |
| 2024-03-05 | 9.8 | 2023-12-29 | 11.5 |
| 2024-03-04 | 9.9 | 2023-12-28 | 11.3 |
| 2024-03-01 | 10.0 | 2023-12-27 | At Loss |
| 2024-02-29 | 10.1 | 2023-12-22 | At Loss |
| 2024-02-28 | 10.3 | 2023-12-21 | At Loss |
| 2024-02-27 | 10.4 | 2023-12-20 | At Loss |
| 2024-02-26 | 10.2 | 2023-12-19 | At Loss |
| 2024-02-23 | 10.4 | 2023-12-18 | At Loss |
| 2024-02-22 | 11.2 | 2023-12-15 | At Loss |
| 2024-02-21 | 11.0 | 2023-12-14 | At Loss |
| 2024-02-20 | 11.2 | 2023-12-13 | At Loss |
Galapagos NV (FRA:GXE) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Galapagos NV
ISIN : BE0003818359
Share Class Description:
FRA:GXE: Ordinary SharesCompare
Compare
Traded in other countries / regions
GLPG.USAGLPG.Netherlands0JXZ.UKGXE.GermanyGLPG.AustriaG1LP34.BrazilGLPG.BelgiumGLPG.Mexico IPO Date
2005-06-27Description
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers